Clinical Trials
65 trialsDouble-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
Second Affiliated Hospital of Nanchang University
NIBCUN
Sun Yat-sen University
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Shanghai Chest Hospital
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Georgetown University
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Shanghai Pulmonary Hospital, Shanghai, China
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Ruijin Hospital
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
BECOME
Hunan Province Tumor Hospital
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
Second Affiliated Hospital of Guangzhou Medical University
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Second Affiliated Hospital of Guangzhou Medical University
PTST_PALBEVA
Lebanese University
NТО-RAS
N.N. Petrov National Medical Research Center of Oncology
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Ultimate
Intergroupe Francophone de Cancerologie Thoracique
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Rutgers, The State University of New Jersey
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
SCRI Development Innovations, LLC
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
Guangdong Association of Clinical Trials
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
The Effects of Preoperative Bevacizumab on Perioperative Complications
Second Affiliated Hospital, School of Medicine, Zhejiang University
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Psychometric Properties of the EORTC QLQ-LC29
University Hospital Regensburg
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Northwestern University
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
Swiss Cancer Institute
Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).
Swiss Cancer Institute
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
University of Massachusetts, Worcester
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
HCH003
Holy Cross Hospital, Florida
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Masonic Cancer Center, University of Minnesota
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
UNC Lineberger Comprehensive Cancer Center
Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Stanford University
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Stanford University
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
MIMEB
University of Cologne